Health Industry Resistance Grows Over Trump's Vaccine Overhaul Plans

President-elect Trump's proposals to overhaul the U.S. childhood vaccination framework are encountering significant opposition from physicians and pharmaceutical leaders, as reported by STAT News. The proposed changes would alter how and when American children receive immunizations, raising concerns among medical professionals about potential disruptions to public health safeguards and the established vaccine schedule. Industry stakeholders are pushing back, citing risks to vaccine efficacy, safety monitoring, and supply chain stability. The friction underscores a widening gap between the incoming administration's policy ambitions and the consensus of the medical establishment. Doctors emphasize decades of clinical data supporting current vaccine timelines, while pharmaceutical companies worry about regulatory uncertainty and potential liability. STAT's reporting indicates that negotiations have been tense, with no clear compromise emerging. The administration seeks to "reform" the system, but the health industry's resistance highlights the complexities and potential risks of altering a well-established public health framework. The outcome remains uncertain as both sides dig in, with implications for child health and the integrity of the nation's immunization program.